HBsAg Decline After Pegylated-interferon-α in e Antigen Positive Chronic Hepatitis B With Nucleoside Maintenance
Status:
Unknown status
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
This study proposes to compare the effect of 48 weeks exposure to pegylated interferon alpha
vs. nucleoside analogue (NA) on hepatitis B e antigen (HBeAg) seroconversion and HBsAg levels
in nucleoside analogue controlled HBeAg-positive chronic hepatitis B (CHB) patients who have
an undetectable hepatitis B virus (HBV) viral load at least 1 years.